LCD-L34635
Document details
Summary
The upcoming Local Coverage Determination (LCD) for Botulinum Toxin Type A & B by WPS is likely to impact billing significantly by defining specific indications and usage guidelines. Providers will neNew LCD on Botulinum Toxin by WPS impacts billing practices.
Affected codes
ICD-10-CM
Affected specialty
Pain Management alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34635&ver=37CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA005010 · Pain Management
The billing pathway for DEMEROL cannot be determined until the FDA label publishes further details regarding its billing status. Billing teams should verify against the FDA label for updated informati
View alertPolicy FDA-NDA011483 · Pain Management
The billing impact of SYNALGOS-DC will be classified under Part D due to its oral route of administration. Billing teams should verify the FDA label for precise billing details as they become availabl
View alertPolicy FDA-NDA022304 · Pain Management
The drug tapentadol hydrochloride is administered orally and is classified under Part D of Medicare billing. Billing teams should verify against the FDA label for any specific billing details once pub
View alertPolicy FDA-NDA202080 · Pain Management
As OXAYDO is administered orally in tablet form, it will be billed under Part D. The exact billing details may vary, so billing teams should verify the payment methodology once the FDA label is publis
View alert